{"favorite_id": 3842, "calc_type": "calculator", "dosing": false, "full_title_en": "Revised Multiple Myeloma International Staging System (R-ISS)", "short_title_en": "Revised Myeloma ISS", "medium_description_en": "Prognostication tool for myeloma patients based on the genetics and other routinely used lab values in conjunction with the original ISS Staging System.", "short_description_en": "Prognostication of myeloma.", "before_use": "", "instructions_en": "<p>Use only in patients recently diagnosed with multiple myeloma. Do not use in patients with relapsed myeloma, smoldering myeloma or MGUS.</p>", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Multiple Myeloma", "Hematologic Malignancy"], "specialty_en": ["Hematology and Oncology", "Internal Medicine"], "chief_complaint_en": ["Weakness"], "system_en": ["Hematologic"], "search_abbreviation_en": ["myeloma", "microglobulin", "albumin", "multiple myeloma", "mm", "riss", "revised myeloma"], "slug": "revised-multiple-myeloma-international-staging-system-r-iss", "seo": {"meta_description_en": "The Revised multiple Myeloma International Staging System (ISS) stages multiple myeloma patients based on genetics and routine lab values in conjunction with the original ISS.", "keywords_en": "MISS, Multiple Myeloma staging system, multiple myeloma International Prognostic Index, ISS, MMISS, MM, r-iss, revised ISS, revised myeloma staging"}, "content": {"how_to_use": {"use_case_en": "<p>Newly diagnosed MM patients. Its utility has NOT been validated in relapsed myeloma, smoldering myeloma or MGUS patients.</p>", "pearls_pitfalls_en": "<ul> <li>The revised International Staging System (R-ISS) for multiple myeloma was developed to better prognosticate long term outcomes of myeloma patients using easily obtained and routinely used prognostic variables.</li> <li>It includes the parameters from the International Staging System (ISS), as well as cytogenetic abnormalities (CA) serum lactate dehydrogenase (LDH).</li> <li>The R-ISS creates 3 subgroups with significantly different overall survival: <ul> <li>Stage I: 82%</li> <li>Stage II: 62%</li> <li>Stage III: 40%</li> </ul> </li> <li>It risk-stratifies multiple myeloma patients better than the original ISS.</li> <li>40% of patients in the data set were not transplant eligible, which reflects a more real-world population than does previous studies</li> </ul>", "why_use_en": "<ul><li>Provides better discrimination of prognosis for MM by using simple, readily available variables.</li><li>Reliable, validated tool that may have a role in upfront risk stratification in future clinical trials, and also may help patients understand their prognosis better.</li></ul>"}, "next_steps": {"advice_en": "<p>Many MM patients are treated through clinical trials. Physicians may consider referring patients to academic treatment centers if they are eligible and willing to receive transplantation, not only to discuss standard treatment options, but also to consider clinical trial options.</p>", "management_en": "<ul> <li>Current staging systems provide prognostic information and are useful for stratification and data assessments/comparisons.</li> <li>The R-ISS, though a more robust powerful prognostic tool compared to ISS, is NOT directly used to alter treatment recommendations outside of a clinical trial at this time.</li> </ul>", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">First, assign ISS stage:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"107\" /><col width=\"60\" /><col width=\"66\" /><col width=\"73\" /></colgroup>\n<tbody>\n<tr>\n<td colspan=\"2\" rowspan=\"2\"></td>\n<td colspan=\"2\">\n<p dir=\"ltr\"><strong>Serum albumin, g/dL</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><em>&ge;3.5 </em></p>\n</td>\n<td>\n<p dir=\"ltr\"><em>&lt;3.5</em></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"3\">\n<p dir=\"ltr\"><strong>Serum &beta;2 microglobulin, mg/L</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><em>&lt;3.5</em></p>\n</td>\n<td>\n<p dir=\"ltr\">ISS I</p>\n</td>\n<td>\n<p dir=\"ltr\">ISS II</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><em>3.5-5.4</em></p>\n</td>\n<td>\n<p dir=\"ltr\">ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\">ISS II</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><em>&ge;5.5</em></p>\n</td>\n<td>\n<p dir=\"ltr\">ISS III</p>\n</td>\n<td>\n<p dir=\"ltr\">ISS III</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>\n<p dir=\"ltr\">Then, stage R-ISS according to iFISH and LDH:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"91\" /><col width=\"90\" /><col width=\"88\" /><col width=\"91\" /><col width=\"45\" /></colgroup>\n<tbody>\n<tr>\n<td rowspan=\"2\"></td>\n<td colspan=\"2\"><br />\n<p dir=\"ltr\"><strong>High-risk cytogenetic abnormalities by iFISH*</strong></p>\n</td>\n<td colspan=\"2\" rowspan=\"2\"></td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><em>No</em></p>\n</td>\n<td>\n<p dir=\"ltr\"><em>Yes</em></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><strong>ISS I</strong></p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS I</p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\"><em>Normal</em></p>\n</td>\n<td rowspan=\"6\">\n<p dir=\"ltr\"><strong>LDH</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\"><em>High</em></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><strong>ISS II</strong></p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\"><em>Normal</em></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\"><em>High</em></p>\n</td>\n</tr>\n<tr>\n<td rowspan=\"2\">\n<p dir=\"ltr\"><strong>ISS III</strong></p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS II</p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS III</p>\n</td>\n<td>\n<p dir=\"ltr\"><em>Normal</em></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">R-ISS III</p>\n</td>\n<td>\n<p dir=\"ltr\">R-ISS III</p>\n</td>\n<td>\n<p dir=\"ltr\"><em>High</em></p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p></p>\n<p dir=\"ltr\">*High-risk&nbsp;= presence of del(17p) and/or translocation t(4;14) and/or translocation t(14;16).</p>", "more_info_en": "<p><strong>R-ISS interpretation:</strong></p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered table-hover\">\n<tbody>\n<tr>\n<th>R-ISS Stage</th>\n<th>Median progression-free survival</th>\n</tr>\n<tr>\n<td>I</td>\n<td>66 months</td>\n</tr>\n<tr>\n<td>II</td>\n<td>42 months</td>\n</tr>\n<tr>\n<td>III</td>\n<td>29 months</td>\n</tr>\n</tbody>\n</table>\n</div>", "evidence_based_medicine_en": "<ul> <li>The revised ISS is based on the original ISS for MM and has been refined further to include validated and reliable prognostic factors for MM, including ISS score, cytogenetic abnormalities, and LDH.</li> <li>It identifies 3 groups with clearly different outcomes and recharacterized ~25% of patients who would have been identified as good risk (misclassified as &ldquo;good prognosis&rdquo;) using only one of the validated factors into a higher risk category.</li> <li>Unlike several other studies, the data set includes many patients (40%) that were not transplant eligible, thus reflecting a &ldquo;real-world&rdquo; population.</li> </ul>", "references_list": {"Original/Primary Reference": [{"href": "http://jco.ascopubs.org/content/33/26/2863", "text": "Palumbo A, et. al. Revised International Staging System for Multiple Myeloma: a Report From International Myeloma Working Group. JCO 2015; 33: 2863-2869."}], "Other References": [{"href": "https://www.myeloma.org/publications", "text": "International Myeloma Foundation. International Staging System. April 2002."}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/15809451", "text": "Greipp PR, et. al. International Staging System for Multiple Myeloma. JCO 2005; 23:3412-3420."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "<p>Randall (Randy) Pierce is in private practice with Northwest Georgia Oncology Centers in Carrollton, Georgia, where he has been in practice since 1998. After graduating from the University of Georgia in 1988, he attended medical school at the Medical College of Georgia. His internal medicine residency and hematology/oncology training were completed at Wake Forest University/Baptist Medical Center in 1998. Dr. Pierce treats most malignancies and has a special interest in myeloma and lymphoma. He is married, has 3 children, and enjoys playing tennis and deep sea fishing.</p>", "firstName": "Randall", "img": "randall-pierce.jpg", "lastName": "Pierce", "name": "Randall Pierce, MD", "target": "randall-pierce", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Antonio Palumbo", "creator_info": {"about_en": "<p>Antonio Palumbo is chief of the Myeloma Unit of the Department of Oncology, Section of Hematology at the University of Torino. He is currently a member of the Board of Directors of the International Myeloma Society. Dr. Palumbo's research focuses on plasma cell dyscrasia, and the pathogenesis and treatment of multiple myeloma.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/Dr.-Antonio-Palumbo1.jpg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Palumbo+A%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Serum \u03b22 microglobulin", "name": "micro", "options": [{"label": "<3.5 mg/L", "value": 0}, {"label": "3.5-5.4  mg/L", "value": 1}, {"label": ">5.4 mg/L", "value": 2}], "conditionality": "", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Serum albumin", "name": "alb", "options": [{"label": "<3.5 g/dL", "value": 0}, {"label": "\u22653.5 g/dL", "value": 1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "radio", "label_en": "CA by iFISH", "name": "ca", "options": [{"label": "Standard risk", "value": 0}, {"label": "High risk", "value": 1}], "conditionality": "", "show_points": false, "tips_en": "High risk defined as: presence of del(17p) and/or translocation t(4;14) and/or translocation t(14;16)", "optional": false}, {"type": "radio", "label_en": "LDH", "name": "ldh", "options": [{"label": "Normal (< upper limit of normal)", "value": 0}, {"label": "High (> upper limit of normal)", "value": 1}], "conditionality": "", "show_points": false, "optional": false}], "md5": "0c1914b1ce5f5ad53d90d6a0951c2081", "related_calcs": [{"calcId": 3841, "short_title_en": "<p>Multiple Myeloma ISS</p>", "slug": "multiple-myeloma-international-staging-system-iss"}, {"calcId": 3929, "short_title_en": "Asymptomatic Myeloma Prognosis", "slug": "asymptomatic-myeloma-prognosis"}, {"calcId": 10233, "short_title_en": "Multiple Myeloma Diagnostic Criteria", "slug": "multiple-myeloma-diagnostic-criteria"}]}